The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer’s disease

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.13, Iss.1, 2004-01, pp. : 69-72

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The presenilins as potential drug targets in Alzheimer’s disease

By Cupers P. Annaert W.G. Strooper B.D.

Expert Opinion on Therapeutic Targets, Vol. 3, Iss. 3, 1999-09 ,pp. : 413-422

Informa Healthcare

Access to resources Recommend Favorite

Potential therapeutic targets for Alzheimer’s disease

By McKeon-O’Malley C. Saunders A.J. Bush A.I. Tanzi R.E.

Expert Opinion on Therapeutic Targets, Vol. 2, Iss. 2, 1998-12 ,pp. : 157-179

Informa Healthcare

Access to resources Recommend Favorite

Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease

By Beher Dirk Graham Samuel L

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 11, 2005-11 ,pp. : 1385-1409

Informa Healthcare

Access to resources Recommend Favorite

Alzheimer’s Disease

Cells Tissues Organs, Vol. 162, Iss. 1, 1998-10 ,pp. : 46-55

Karger

Access to resources Recommend Favorite

Cyclo-Oxygenase-2 Inhibitors: Rationale and Therapeutic Potential for Alzheimers Disease

By McGeer P.L.

Drugs & Aging, Vol. 17, Iss. 1, 2000-07 ,pp. : 1-11

Adis International

Access to resources Recommend Favorite